Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at SunTrust Banks issued their Q3 2017 earnings estimates for Abeona Therapeutics in a report released on Wednesday. SunTrust Banks analyst E. Nash expects that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter. SunTrust Banks has a “Buy” rating and a $26.00 price objective on the stock. SunTrust Banks also issued estimates for Abeona Therapeutics’ Q4 2017 earnings at ($0.24) EPS, FY2017 earnings at ($0.81) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.30) EPS, Q3 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.28) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($1.09) EPS, FY2020 earnings at ($1.04) EPS and FY2021 earnings at ($0.80) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. TRADEMARK VIOLATION NOTICE: “Abeona Therapeutics Inc. Forecasted to Earn Q3 2017 Earnings of ($0.23) Per Share (ABEO)” was published by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/11/11/abeona-therapeutics-inc-forecasted-to-earn-q3-2017-earnings-of-0-23-per-share-abeo.html.

Several other brokerages have also weighed in on ABEO. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, September 18th. Maxim Group set a $17.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 16th. Citigroup Inc. began coverage on Abeona Therapeutics in a report on Tuesday, October 10th. They set a “buy” rating and a $32.00 price objective for the company. BidaskClub lowered Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. Abeona Therapeutics has a consensus rating of “Buy” and a consensus target price of $22.90.

Abeona Therapeutics (ABEO) opened at $15.25 on Friday. Abeona Therapeutics has a twelve month low of $4.05 and a twelve month high of $22.75.

Large investors have recently made changes to their positions in the company. State of Wisconsin Investment Board bought a new position in shares of Abeona Therapeutics during the second quarter valued at about $122,000. Rhumbline Advisers bought a new stake in shares of Abeona Therapeutics in the second quarter worth about $190,000. Wells Fargo & Company MN grew its stake in shares of Abeona Therapeutics by 3,421.8% in the third quarter. Wells Fargo & Company MN now owns 35,218 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 34,218 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in Abeona Therapeutics in the second quarter worth about $264,000. Finally, Bank of New York Mellon Corp lifted its holdings in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 23,358 shares during the period. 33.35% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.